Erratum: Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients (Proceedings of the National Academy of Sciences of the United States of America (2013) 110 (3483-3488) DOI: 10.1073/pnas.1222435110);Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 9, 2013, Pages 3483-3488

  Emerling, Brooke M ^a,b   Benes, Cyril H ^a,c   Poulogiannis, George ^a,b   Bell, Eric L ^d   Courtney, Kevin ^e,f   Liu, Hui ^a,b   Choo Wing, Rayman ^a,b   Bellinger, Gary ^a,b   Tsukazawa, Kazumi S ^a,b   Brown, Victoria ^a,e   Signoretti, Sabina ^a,e   Soltoff, Stephen P ^b   Cantley, Lewis C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Kidney cancer; Oxygen deprivation

Indexed keywords

CUB DOMAIN CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MEMBRANE PROTEIN; SHORT HAIRPIN RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE CONTROL; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR GROWTH;

EID: 84874491920     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2112097118     Document Type: Erratum

References (34)

1. Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6): 1190-1203.
2. Scherl-Mostageer M, et al. (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20(32): 4402-4408.
3. Awakura Y, et al. (2008) Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134(12): 1363-1369.
4. Razorenova OV, et al. (2011) VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCdelta-driven migration. Proc Natl Acad Sci USA 108(5): 1931-1936.
5. Hooper JD, et al. (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22(12): 1783-1794.
6. Perry SE, et al. (2007) Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 581(6): 1137-1142.
7. Miyazawa Y, et al. (2010) CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70(12): 5136-5146.
8. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24(34): 5333-5343.
9. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM (2009) The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol 174(5): 1756-1765.
10. Uekita T, et al. (2007) CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 27(21): 7649-7660.
11. Uekita T, et al. (2008) CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 172(6): 1729-1739.
12. Ikeda J, et al. (2009) Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 100(3): 429-433.
13. Deryugina EI, et al. (2009) Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 7(8): 1197-1211.
14. Fukuchi K, et al. (2010) Inhibition of tumor metastasis: Functional immune modulation of the CUB domain containing protein 1. Mol Pharm 7(1): 245-253.
15. Benes CH, et al. (2005) The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell 121(2): 271-280.
16. Liu H, et al. (2011) CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA 108(4): 1379-1384.
17. Ivan M, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292(5516): 464-468.
18. Jaakkola P, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516): 468-472.
19. Bell EL, et al. (2007) The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177(6): 1029-1036.
20. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basichelix- loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12): 5510-5514.
21. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10): 721-732.
22. Gordan JD, Simon MC (2007) Hypoxia-inducible factors: Central regulators of the tumor phenotype. Curr Opin Genet Dev 17(1): 71-77.
23. Raval RR, et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13): 5675-5686.
24. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1(3): 237-246.
25. Maranchie JK, et al. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1(3): 247-255.
26. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1(3):E83.
27. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O (2004) Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2(2): 89-95.
28. Shen C, et al. (2011) Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 1(3): 222-235.
29. He Y, et al. (2010) Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem 285(34): 26162-26173.
30. Benes CH, Poulogiannis G, Cantley LC, Soltoff SP (2012) The SRC-associated protein CUB domain-containing protein-1 regulates adhesion and motility. Oncogene 31(5): 653-663.
31. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545): 1337-1340.
32. Epstein AC, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107(1): 43-54.
33. Moffat J, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124(6): 1283-1298.
34. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45, 10.1093/nar/29.9.e45.